Αρχειοθήκη ιστολογίου

Πέμπτη 17 Μαρτίου 2016

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

Cancer

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/1Ma9ofu
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου